IP Library Granted Patent US 8,785,395
Granted Patent B2
US 8,785,395 · App. 13/643,592 · Granted Jul 22, 2014

Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases

Inventors: Darwin J. Prockop (Philadelphia, PA); Joo Youn Oh (Temple, TX); Gavin W. Roddy (Temple, TX); Robert Rosa (Holland, TX); Barry A. Berkowitz (Framingham, MA)
Assignees: The Texas A & M University System; Temple Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,785,395
App. No.
13/643,592
Granted
Jul 22, 2014
Kind
B2
Abstract

The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties. The invention includes administration of TSG-6, STC-1, or a combination thereof to the ocular as a treatment for an ocular disease, disorder or condition in a mammal.

Claims (8)

1. A method of treating an injury to the cornea in a patient, comprising:

administering to said patient a therapeutic agent for treating an injury to the cornea consisting of TSG-6 protein or a biologically active fragment, or variant thereof, wherein said TSG-6 protein or biologically active fragment, or variant thereof is administered in an amount effective to treat said injury to the cornea in said patient.

2. The method of claim 1 , wherein said injury to the cornea is an injury to the corneal stromal areas.

3. The method of claim 1 wherein said TSG-6 protein or a biologically active fragment, or variant thereof is administered to said patient in an amount of from about 0.01 mg to about 20 mg per kilogram of body weight.

4. The method of claim 3 wherein said TSG-6 protein or a biologically active fragment, or variant thereof is administered to said patient in an amount of from about 0.1 mg to about 5 mg per kilogram of body weight.

5. The method of claim 1 wherein said therapeutic agent for treating an injury to the cornea is administered intraocularly.

6. A method of treating an injury to the cornea in a patient, comprising:

administering to the cornea of said patient eye drops containing a therapeutic agent for treating an injury to the cornea consisting of TSG-6 protein or a biologically active fragment, or variant thereof, and wherein said TSG-6 protein or biologically active fragment, variant, or analog thereof is contained in said eye drops in an amount effective to treat said injury to the cornea in said patient.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 29, 2018
From: TEXAS A&M UNIVERSITY SYSTEM
To: NIH - DEITR
Reel/Frame 045181/0058 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2014
From: THE TEXAS A&M UNIVERSITY SYSTEM
To: SCOTT & WHITE HEALTHCARE
Reel/Frame 032588/0377 →
Continuity (3)
Provisional Application 61464172 · Feb 28, 2011
Provisional Application 61330735 · May 3, 2010
Related Publication 20130039924A1 · Feb 14, 2013